Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Eledon Pharmaceuticals, Inc. (ELDN : NSDQ)
 
 • Company Description   
Eledon Pharmaceuticals Inc. is a clinical stage biotechnology company. It develop treatments for an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Eledon Pharmaceuticals Inc., formerly known as Novus Therapeutics Inc., is based in IRVINE, Calif.

Number of Employees: 12

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.20 Daily Weekly Monthly
20 Day Moving Average: 22,566 shares
Shares Outstanding: 13.76 (millions)
Market Capitalization: $44.02 (millions)
Beta: 1.94
52 Week High: $10.20
52 Week Low: $2.27
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.00% 9.49%
12 Week -16.67% -6.34%
Year To Date -27.44% -11.35%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
19900 MACARTHUR BOULEVARD SUITE 550
-
IRVINE,CA 92612
USA
ph: 949-238-8090
fax: -
investors@eledon.com http://www.eledon.com
 
 • General Corporate Information   
Officers
David-Alexandre C. Gros - Chief Executive Officer and Director
Keith A. Katkin - Chairman
Paul Little - Chief Financial Officer
Jan Hillson - Director
Gary A. Lyons - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 28617K101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 13.76
Most Recent Split Date: 10.00 (0.06:1)
Beta: 1.94
Market Capitalization: $44.02 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.72 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.59 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.28
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -21.05%
vs. Previous Quarter: -16.95%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -21.42
12/31/21 - -19.80
09/30/21 - -17.47
ROA
03/31/22 - -20.69
12/31/21 - -19.07
09/30/21 - -16.85
Current Ratio
03/31/22 - 26.82
12/31/21 - 20.07
09/30/21 - 23.62
Quick Ratio
03/31/22 - 26.82
12/31/21 - 20.07
09/30/21 - 23.62
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 11.36
12/31/21 - 11.46
09/30/21 - 11.94
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©